We aim to translate breakthrough science into innovative oncology medicines

Research and Development

Switzerland is one of more than fifty countries in which MSD conducts clinical research. The growing Swiss oncology clinical trial program is coordinated at our site in the Citybay building in Lucerne.

Also our site in Schachen in the canton of Lucerne plays an important role in providing new innovative medicines. Around 330 employees from currently 15 nations work here to

• develop and analyze new biotechnological active ingredients
• test new drugs
• conduct stability studies and supply drugs for worldwide clinical trials during development.

Access to Care

Improving access to cancer care is our strategic priority. We are working with the entire cancer community to help patients gain access to the oncology medicines that they need and to expand the provision of quality cancer care.

In our office at the Citybay building in Lucerne, the Swiss Oncology team is

• collaborating with authorities and institutions to ensure access to our medicines
• working on solutions how to continuously improve the support of healthcare professionals and patients in the treatment of cancer
• interacting with Oncologists, Scientific leaders and patient organizations to gain insight into market and customer needs.

Partnerships

MSD Switzerland has engaged in collaborative efforts to raise the awareness of cancer and improve its prevention, including

• the creation of a platform for discussions on lung cancer policies
• the setup of a think tank to address the challenges of a fast-changing landscape in the immuno-oncology field.

We participate in several initiatives to support patients with cancer. These include:

• a website for disease management
• campaigns to educate the public about early signs and detection
• a partnership to improve sustainable cancer care all-can.org.